Literature DB >> 8806679

Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase.

S Baasner1, H von Melchner, T Klenner, P Hilgard, T Beckers.   

Abstract

In the present study we describe the reversible transformation of NIH3T3 fibroblasts by overexpression of the HER2/c-erbB2 receptor tyrosine kinase. Cell lines expressing HER2 under control of a tetracycline-responsive promoter were isolated. Induction of HER2 expression resulted in cellular transformation in vitro as depicted by growth in soft agar and focus formation in tissue culture. Subsequent treatment of these cells with the effector anhydrotetracyline switched-off HER2 expression and induced morphological and functional changes characteristic for non-transformed cells. Subcutaneous transplantation of cells in nude mice resulted in the formation of solid tumors. Interestingly tumor formation was completely suppressed by treatment of the animals with anhydrotetracyline. Our findings indicate that overexpression of HER2 induces the transformed phenotype of NIH3T3 cells and is required for tumor formation and progression in nude mice. By linking the expression of the marker gene secreted placental alkaline phosphatase to the expression of HER2, a sensitive monitoring of tumor development in nude mice was feasible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806679

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Conditional control of gene expression in the mammary gland.

Authors:  P A Furth
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

Review 2.  Perspectives of HER2-targeting in gastric and esophageal cancer.

Authors:  James N Gerson; Sam Skariah; Crystal S Denlinger; Igor Astsaturov
Journal:  Expert Opin Investig Drugs       Date:  2017-05       Impact factor: 6.206

3.  Genomewide trapping of genes that encode secreted and transmembrane proteins repressed by oncogenic signaling.

Authors:  M Gebauer; H von Melchner; T Beckers
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

4.  Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.

Authors:  Shaker Abuharbeid; Jürgen Apel; Gerhard Zugmaier; Cornelius Knabbe; Martin Sander; Sandra Gilbert; Frank Czubayko; Achim Aigner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-02-08       Impact factor: 3.000

Review 5.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 6.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

7.  Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.

Authors:  Elise M J van der Logt; Deborah A J Kuperus; Jan W van Setten; Marius C van den Heuvel; James E Boers; Ed Schuuring; Robby E Kibbelaar
Journal:  PLoS One       Date:  2015-04-06       Impact factor: 3.240

8.  Transcriptional Targeting in Cancer Gene Therapy.

Authors:  Tracy Robson; David G. Hirst
Journal:  J Biomed Biotechnol       Date:  2003

9.  Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.

Authors:  M Hermes; W Schormann; M Brulport; K Uhlemann; F Lupatsch; L C Horn; A Schumann; C Allgaier; M Weishaupt; K Engeland; G A Müller; J Mössner; A Bauer; I B Schiffer; S Gebhard; M Schmidt; E Lausch; D Prawitt; C Wilhelm; J G Hengstler
Journal:  Br J Cancer       Date:  2008-04-29       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.